Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Ascentage Pharma Group Inc.

2 clinical trials · 2 recruiting · INDUSTRY

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Ascentage Pharma Group Inc.

RECRUITINGPhase 1NCT06687070

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

An open, multicenter, dose-exploring Phase I trial include Part A and Part B to evaluate the safety, tolerability and efficacy of APG-2449.

Sponsor: Ascentage Pharma Group Inc.Enrolling: 501 location
Platinum-resistant Recurrent Ovarian CancerAdvanced Solid Tumor
RECRUITINGPhase 1NCT03917043

APG-2449 in Patients With Advanced Solid Tumors

APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449...

Sponsor: Ascentage Pharma Group Inc.Enrolling: 1659 locations
Advanced Solid CancerNon Small Cell Lung CancerEsophageal Cancer+2